Dassault Systèmes has reported strong second-quarter results for 2026, reaffirming its full-year objectives while expanding its footprint in the Life Sciences sector through the acquisition of ArisGlobal.
The company achieved a 4% increase in total revenue during Q2 2026, largely attributed to an 8% rise in subscription services. Notably, both 3D EXPERIENCE and cloud software revenues experienced a 14% boost, primarily driven by demand in the manufacturing industries. The annual run rate also reflected healthy growth, indicating a robust business model with operating margins at 30% and an 8% increase in non-IFRS diluted earnings per share.
CEO Pascal Daloz emphasized the company's strategic focus on Life Sciences, highlighting the importance of a unified platform that integrates discovery, clinical development, and regulatory intelligence. The acquisition of ArisGlobal is seen as a pivotal move to create an AI-driven platform that connects real-world and virtual evidence, aimed at accelerating innovation in therapies while ensuring compliance.
Looking ahead, CFO Rouven Bergmann noted that the company is on track to meet its financial goals for the year, underlining the significance of the ArisGlobal acquisition for enhancing their leadership in Life Sciences. With ongoing advancements in AI capabilities, Dassault Systèmes is positioning itself as a frontrunner in the digital transformation of the sector, aiming to deliver faster and more effective solutions to healthcare challenges.